Chemopreventive therapeutics. Inhalation therapies for lung cancer and bronchial premalignancy.

Missak Haigentz, Roman Perez-Soler

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The lung cancer epidemic is not expected to abate in the next two decades. Smoking cessation campaigns have not been successful in reducing the prevalence of smoking to < 25% of the adult population in the US. Among high school students, the prevalence of smoking is increasing (27.5% in 1991; 36.4% in 1997) (43). In addition, only 1 in 8 heavy smokers develop lung cancer and about 20% of patients with lung cancer have no history of active or passive smoking, thus indicating that genetic predisposing factors and other unidentified carcinogens play a crucial role in the etiology of this disease. The bronchial epithelium is like an internal skin where lung cancer originates after chronic exposure to airborne carcinogens in a predisposed host. Although the bronchial epithelium is not readily examinable, it is easily accessible to therapeutic intervention by using inhaled therapeutics. We hope to extend our findings using direct wild-type p53 gene replacement via intratracheal and aerosolized administrations in mice to NSCLC patients with p53 mutations. We also plan on utilizing aerosolized chemical agents to activate endogenous mechanisms of cytoprotection. If, in clinical trials, evidence of effective cytoprotection is observed in the absence of intolerable side effects, further exploration of this new strategy for the control and prevention of a neoplastic disease that accounts for a third of all cancer-related deaths will be fully justified.

Original languageEnglish (US)
Pages (from-to)771-780
Number of pages10
JournalMethods in molecular medicine
Volume75
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Respiratory Therapy
Lung Neoplasms
Cytoprotection
Carcinogens
Epithelium
Smoking
Tobacco Smoke Pollution
p53 Genes
Skin Neoplasms
Smoking Cessation
Therapeutics
Causality
Clinical Trials
Students
Mutation
Population
Neoplasms

Cite this

@article{7d9ba70f022a4bf29d67cc72d9632e9c,
title = "Chemopreventive therapeutics. Inhalation therapies for lung cancer and bronchial premalignancy.",
abstract = "The lung cancer epidemic is not expected to abate in the next two decades. Smoking cessation campaigns have not been successful in reducing the prevalence of smoking to < 25{\%} of the adult population in the US. Among high school students, the prevalence of smoking is increasing (27.5{\%} in 1991; 36.4{\%} in 1997) (43). In addition, only 1 in 8 heavy smokers develop lung cancer and about 20{\%} of patients with lung cancer have no history of active or passive smoking, thus indicating that genetic predisposing factors and other unidentified carcinogens play a crucial role in the etiology of this disease. The bronchial epithelium is like an internal skin where lung cancer originates after chronic exposure to airborne carcinogens in a predisposed host. Although the bronchial epithelium is not readily examinable, it is easily accessible to therapeutic intervention by using inhaled therapeutics. We hope to extend our findings using direct wild-type p53 gene replacement via intratracheal and aerosolized administrations in mice to NSCLC patients with p53 mutations. We also plan on utilizing aerosolized chemical agents to activate endogenous mechanisms of cytoprotection. If, in clinical trials, evidence of effective cytoprotection is observed in the absence of intolerable side effects, further exploration of this new strategy for the control and prevention of a neoplastic disease that accounts for a third of all cancer-related deaths will be fully justified.",
author = "Missak Haigentz and Roman Perez-Soler",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "75",
pages = "771--780",
journal = "Methods in molecular medicine",
issn = "1543-1894",
publisher = "Humana Press",

}

Chemopreventive therapeutics. Inhalation therapies for lung cancer and bronchial premalignancy. / Haigentz, Missak; Perez-Soler, Roman.

In: Methods in molecular medicine, Vol. 75, 01.01.2003, p. 771-780.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemopreventive therapeutics. Inhalation therapies for lung cancer and bronchial premalignancy.

AU - Haigentz, Missak

AU - Perez-Soler, Roman

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The lung cancer epidemic is not expected to abate in the next two decades. Smoking cessation campaigns have not been successful in reducing the prevalence of smoking to < 25% of the adult population in the US. Among high school students, the prevalence of smoking is increasing (27.5% in 1991; 36.4% in 1997) (43). In addition, only 1 in 8 heavy smokers develop lung cancer and about 20% of patients with lung cancer have no history of active or passive smoking, thus indicating that genetic predisposing factors and other unidentified carcinogens play a crucial role in the etiology of this disease. The bronchial epithelium is like an internal skin where lung cancer originates after chronic exposure to airborne carcinogens in a predisposed host. Although the bronchial epithelium is not readily examinable, it is easily accessible to therapeutic intervention by using inhaled therapeutics. We hope to extend our findings using direct wild-type p53 gene replacement via intratracheal and aerosolized administrations in mice to NSCLC patients with p53 mutations. We also plan on utilizing aerosolized chemical agents to activate endogenous mechanisms of cytoprotection. If, in clinical trials, evidence of effective cytoprotection is observed in the absence of intolerable side effects, further exploration of this new strategy for the control and prevention of a neoplastic disease that accounts for a third of all cancer-related deaths will be fully justified.

AB - The lung cancer epidemic is not expected to abate in the next two decades. Smoking cessation campaigns have not been successful in reducing the prevalence of smoking to < 25% of the adult population in the US. Among high school students, the prevalence of smoking is increasing (27.5% in 1991; 36.4% in 1997) (43). In addition, only 1 in 8 heavy smokers develop lung cancer and about 20% of patients with lung cancer have no history of active or passive smoking, thus indicating that genetic predisposing factors and other unidentified carcinogens play a crucial role in the etiology of this disease. The bronchial epithelium is like an internal skin where lung cancer originates after chronic exposure to airborne carcinogens in a predisposed host. Although the bronchial epithelium is not readily examinable, it is easily accessible to therapeutic intervention by using inhaled therapeutics. We hope to extend our findings using direct wild-type p53 gene replacement via intratracheal and aerosolized administrations in mice to NSCLC patients with p53 mutations. We also plan on utilizing aerosolized chemical agents to activate endogenous mechanisms of cytoprotection. If, in clinical trials, evidence of effective cytoprotection is observed in the absence of intolerable side effects, further exploration of this new strategy for the control and prevention of a neoplastic disease that accounts for a third of all cancer-related deaths will be fully justified.

UR - http://www.scopus.com/inward/record.url?scp=1842837877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842837877&partnerID=8YFLogxK

M3 - Article

VL - 75

SP - 771

EP - 780

JO - Methods in molecular medicine

JF - Methods in molecular medicine

SN - 1543-1894

ER -